RU2007107167A - Ингибиторы передачи сигнала рецептора vegf и рецептора hgf - Google Patents
Ингибиторы передачи сигнала рецептора vegf и рецептора hgf Download PDFInfo
- Publication number
- RU2007107167A RU2007107167A RU2007107167/04A RU2007107167A RU2007107167A RU 2007107167 A RU2007107167 A RU 2007107167A RU 2007107167/04 A RU2007107167/04 A RU 2007107167/04A RU 2007107167 A RU2007107167 A RU 2007107167A RU 2007107167 A RU2007107167 A RU 2007107167A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- aryl
- heteroaryl
- optionally substituted
- Prior art date
Links
- 108091008605 VEGF receptors Proteins 0.000 title claims 11
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title claims 11
- 102000005962 receptors Human genes 0.000 title claims 11
- 108020003175 receptors Proteins 0.000 title claims 11
- 239000003112 inhibitor Substances 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 192
- 125000000623 heterocyclic group Chemical group 0.000 claims 176
- 125000003118 aryl group Chemical group 0.000 claims 140
- 229910052739 hydrogen Inorganic materials 0.000 claims 129
- 229910052736 halogen Inorganic materials 0.000 claims 127
- 150000002367 halogens Chemical class 0.000 claims 127
- 125000001072 heteroaryl group Chemical group 0.000 claims 123
- 125000001424 substituent group Chemical group 0.000 claims 76
- 229910052799 carbon Inorganic materials 0.000 claims 62
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 50
- 125000000753 cycloalkyl group Chemical group 0.000 claims 49
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 45
- 125000004093 cyano group Chemical group *C#N 0.000 claims 44
- 229910052757 nitrogen Inorganic materials 0.000 claims 42
- -1 —NMe 2 Chemical group 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 39
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 35
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 30
- 239000001257 hydrogen Substances 0.000 claims 29
- 238000000034 method Methods 0.000 claims 24
- 229910052717 sulfur Inorganic materials 0.000 claims 24
- 125000003545 alkoxy group Chemical group 0.000 claims 22
- 125000004432 carbon atom Chemical group C* 0.000 claims 20
- 230000002401 inhibitory effect Effects 0.000 claims 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 18
- 125000004429 atom Chemical group 0.000 claims 17
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 16
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 125000001188 haloalkyl group Chemical group 0.000 claims 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims 11
- 229910052731 fluorine Inorganic materials 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 230000011664 signaling Effects 0.000 claims 11
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 10
- 108091008603 HGF receptors Proteins 0.000 claims 10
- 102000027430 HGF receptors Human genes 0.000 claims 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 8
- 125000004404 heteroalkyl group Chemical group 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims 8
- 230000002062 proliferating effect Effects 0.000 claims 8
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 7
- 125000004953 trihalomethyl group Chemical group 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 239000011737 fluorine Substances 0.000 claims 6
- 239000000460 chlorine Substances 0.000 claims 5
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 230000008054 signal transmission Effects 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 2
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006643 (C2-C6) haloalkenyl group Chemical group 0.000 claims 2
- 125000006644 (C2-C6) haloalkynyl group Chemical group 0.000 claims 2
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59291304P | 2004-07-30 | 2004-07-30 | |
| US60/592,913 | 2004-07-30 | ||
| US68303805P | 2005-05-20 | 2005-05-20 | |
| US60/683,038 | 2005-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007107167A true RU2007107167A (ru) | 2008-09-10 |
Family
ID=35785877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007107167/04A RU2007107167A (ru) | 2004-07-30 | 2005-07-28 | Ингибиторы передачи сигнала рецептора vegf и рецептора hgf |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7772247B2 (https=) |
| EP (1) | EP1781664B1 (https=) |
| JP (1) | JP5096142B2 (https=) |
| KR (1) | KR101257343B1 (https=) |
| CN (1) | CN101031570B (https=) |
| AU (1) | AU2005266803B2 (https=) |
| BR (1) | BRPI0513982A (https=) |
| CA (1) | CA2573538C (https=) |
| ES (1) | ES2438017T3 (https=) |
| IL (1) | IL180788A0 (https=) |
| MX (1) | MX2007001216A (https=) |
| RU (1) | RU2007107167A (https=) |
| WO (1) | WO2006010264A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2619130C2 (ru) * | 2012-06-29 | 2017-05-12 | Бетта Фармасьютикалз Ко., Лтд | НОВЫЕ КОНДЕНСИРОВАННЫЕ ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ с-MET |
| RU2712220C2 (ru) * | 2013-07-31 | 2020-01-27 | Мерк Патент Гмбх | Пиридины, пиримидины и пиразины в качестве ингибиторов тирозинкиназы брутона и их применение |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005118588A1 (ja) * | 2004-06-02 | 2005-12-15 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
| KR101257343B1 (ko) | 2004-07-30 | 2013-04-23 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제 |
| AU2006229343A1 (en) * | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
| WO2006113650A1 (en) * | 2005-04-18 | 2006-10-26 | Khan Saeed R | Design and synthesis of novel tubulin polymerization inhibitors: bonzoylphenyluria (bpu) sulfur analogs |
| CN101796055B (zh) * | 2005-05-20 | 2013-09-04 | 梅特希尔基因公司 | Vegf受体和hgf受体信号的抑制剂 |
| AU2006313456B2 (en) * | 2005-05-20 | 2011-06-23 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
| TW200730527A (en) * | 2005-12-02 | 2007-08-16 | Takeda Pharmaceuticals Co | Fused heterocyclic compound |
| JP2009526761A (ja) * | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| WO2007107005A1 (en) * | 2006-03-22 | 2007-09-27 | Methylgene, Inc. | Inhibitors of protein tyrosine kinase activity |
| JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| BRPI0816064B8 (pt) * | 2007-08-29 | 2021-05-25 | Methylgene Inc | composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica |
| US8907091B2 (en) * | 2007-08-29 | 2014-12-09 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
| BRPI0908573A2 (pt) | 2008-03-05 | 2012-12-25 | Methylgene Inc | inibidores da atividade de proteÍna tirosina quinase |
| EP2340244A4 (en) * | 2008-10-14 | 2012-07-25 | Ning Xi | COMPOUNDS AND APPLICATION PROCEDURES |
| ES2578990T3 (es) * | 2009-03-21 | 2016-08-03 | Sunshine Lake Pharma Co., Ltd. | Derivados de amino éster, sales de los mismos y métodos de uso |
| US8455484B2 (en) * | 2010-04-16 | 2013-06-04 | Methylgene Inc. | Selected inhibitors of protein tyrosine kinase activity |
| KR20130091331A (ko) | 2010-07-16 | 2013-08-16 | 교와 핫꼬 기린 가부시키가이샤 | 함질소 방향족 복소환 유도체 |
| MX2013003019A (es) | 2010-09-15 | 2013-05-28 | Hoffmann La Roche | Compuestos de azabenzotiazol, composiciones y metodos de uso. |
| WO2012118632A1 (en) | 2011-02-28 | 2012-09-07 | Ning Xi | Substituted quinoline compounds and methods of use |
| ES2895918T3 (es) | 2012-02-21 | 2022-02-23 | Towa Pharmaceutical Europe S L | Composiciones farmacéuticas orales de dabigatrán etexilato |
| WO2014022117A1 (en) | 2012-07-28 | 2014-02-06 | Calitor Sciences, Llc | Substituted pyrazolone compounds and methods of use |
| TWI574962B (zh) | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| MX2015010700A (es) | 2013-02-21 | 2017-01-23 | Calitor Sciences Llc | Compuestos heteroaromaticos como moduladores de la p13 cinasa. |
| CN106588943B (zh) | 2015-10-19 | 2018-10-16 | 广东东阳光药业有限公司 | 一种egfr抑制剂的盐、晶型及其用途 |
| CN111032092A (zh) | 2017-06-30 | 2020-04-17 | 韩国科学技术院 | Vegf-grab蛋白与药物的缀合物及其用途 |
| WO2019101178A1 (zh) | 2017-11-24 | 2019-05-31 | 南京明德新药研发股份有限公司 | 作为c-MET/AXL抑制剂的尿嘧啶类化合物 |
| ES2974634T3 (es) | 2018-12-21 | 2024-06-28 | Celgene Corp | Inhibidores de tienopiridinas de RIPK2 |
| JP2025508267A (ja) | 2022-03-04 | 2025-03-21 | パノロス バイオサイエンス インコーポレイテッド | ＶＥＧＦ－Ｇｒａｂ及びＰＤ－１又はＰＤ－Ｌ１拮抗剤を含む併用投与用組成物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| CA2309690A1 (en) | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| CA2333770A1 (en) | 1998-06-04 | 1999-12-09 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| JP2003535867A (ja) | 2000-06-06 | 2003-12-02 | ファイザー プロダクツ インコーポレイテッド | 抗癌剤として有用なチオフェン誘導体 |
| US20020004511A1 (en) | 2000-06-28 | 2002-01-10 | Luzzio Michael Joseph | Thiophene derivatives useful as anticancer agents |
| DE60137273D1 (de) * | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| AU2002345792A1 (en) | 2001-06-21 | 2003-01-08 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| EP2258366B1 (en) * | 2001-06-22 | 2013-04-03 | Kirin Pharma Kabushiki Kaisha | Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
| GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| BR0308162A (pt) | 2002-03-01 | 2004-12-07 | Pfizer | Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso |
| US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| CL2003002287A1 (es) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| DE10335598A1 (de) | 2003-08-04 | 2005-02-24 | Robert Bosch Gmbh | Pedal-Vorrichtung für Kraftfahrzeuge |
| EP1660504B1 (en) | 2003-08-29 | 2008-10-29 | Pfizer Inc. | Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents |
| WO2005052872A1 (en) * | 2003-11-21 | 2005-06-09 | Facil, Llc | Financial transaction system and method |
| WO2005073224A2 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| WO2005121125A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| CA2572331A1 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
| EP1768984B1 (en) | 2004-07-16 | 2010-10-20 | Sunesis Pharmaceuticals, Inc. | Thienopyrimidines useful as aurora kinase inhibitors |
| KR101257343B1 (ko) | 2004-07-30 | 2013-04-23 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제 |
| AU2006229343A1 (en) | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| CN101796055B (zh) * | 2005-05-20 | 2013-09-04 | 梅特希尔基因公司 | Vegf受体和hgf受体信号的抑制剂 |
| AU2006313456B2 (en) * | 2005-05-20 | 2011-06-23 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
-
2005
- 2005-07-28 KR KR1020077005060A patent/KR101257343B1/ko not_active Expired - Fee Related
- 2005-07-28 MX MX2007001216A patent/MX2007001216A/es active IP Right Grant
- 2005-07-28 BR BRPI0513982-1A patent/BRPI0513982A/pt not_active Application Discontinuation
- 2005-07-28 CA CA2573538A patent/CA2573538C/en not_active Expired - Fee Related
- 2005-07-28 JP JP2007522886A patent/JP5096142B2/ja not_active Expired - Fee Related
- 2005-07-28 CN CN2005800331963A patent/CN101031570B/zh not_active Expired - Fee Related
- 2005-07-28 ES ES05770304.3T patent/ES2438017T3/es not_active Expired - Lifetime
- 2005-07-28 EP EP05770304.3A patent/EP1781664B1/en not_active Expired - Lifetime
- 2005-07-28 RU RU2007107167/04A patent/RU2007107167A/ru not_active Application Discontinuation
- 2005-07-28 AU AU2005266803A patent/AU2005266803B2/en not_active Ceased
- 2005-07-28 WO PCT/CA2005/001177 patent/WO2006010264A1/en not_active Ceased
- 2005-07-28 US US11/191,617 patent/US7772247B2/en active Active
-
2007
- 2007-01-18 IL IL180788A patent/IL180788A0/en unknown
-
2010
- 2010-05-06 US US12/775,090 patent/US8470850B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2619130C2 (ru) * | 2012-06-29 | 2017-05-12 | Бетта Фармасьютикалз Ко., Лтд | НОВЫЕ КОНДЕНСИРОВАННЫЕ ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ с-MET |
| RU2712220C2 (ru) * | 2013-07-31 | 2020-01-27 | Мерк Патент Гмбх | Пиридины, пиримидины и пиразины в качестве ингибиторов тирозинкиназы брутона и их применение |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101257343B1 (ko) | 2013-04-23 |
| US7772247B2 (en) | 2010-08-10 |
| WO2006010264A1 (en) | 2006-02-02 |
| EP1781664A4 (en) | 2010-06-02 |
| EP1781664B1 (en) | 2013-09-04 |
| CN101031570A (zh) | 2007-09-05 |
| US20100216766A1 (en) | 2010-08-26 |
| IL180788A0 (en) | 2007-06-03 |
| CA2573538A1 (en) | 2006-02-02 |
| US20060074056A1 (en) | 2006-04-06 |
| EP1781664A1 (en) | 2007-05-09 |
| MX2007001216A (es) | 2007-03-23 |
| BRPI0513982A (pt) | 2007-11-27 |
| CN101031570B (zh) | 2012-09-05 |
| AU2005266803A1 (en) | 2006-02-02 |
| ES2438017T3 (es) | 2014-01-15 |
| CA2573538C (en) | 2014-11-25 |
| JP2008508192A (ja) | 2008-03-21 |
| JP5096142B2 (ja) | 2012-12-12 |
| US8470850B2 (en) | 2013-06-25 |
| AU2005266803B2 (en) | 2011-10-27 |
| KR20070051876A (ko) | 2007-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007107167A (ru) | Ингибиторы передачи сигнала рецептора vegf и рецептора hgf | |
| ES2954514T3 (es) | Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del VIH | |
| JP2010510237A5 (https=) | ||
| RU2472797C2 (ru) | ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА | |
| RU2316326C2 (ru) | Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины | |
| RU2018128318A (ru) | Селективные ингибиторы эстрогеновых рецепторов и их применение | |
| RU2015120478A (ru) | Пери-карбинолы | |
| JP2010501584A5 (https=) | ||
| RU2015126015A (ru) | Новые улавливатели в лечении макулодистрофии | |
| RU2018105549A (ru) | Производные бензодиазепина как ингибиторы rsv | |
| RU2012144751A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| JP2008508192A5 (https=) | ||
| CA2526636A1 (en) | Diaryl ureas for diseases mediated by pdgfr | |
| JP2017504642A5 (https=) | ||
| RU2012153164A (ru) | Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути | |
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| JP2013536193A5 (https=) | ||
| RU2006139258A (ru) | Бензотриазиновые ингибиторы киназ | |
| KR890011591A (ko) | 제약학적 제제 | |
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| RU2013130256A (ru) | Новые циклоспориновые производные для лечения и предупреждения вирусных инфекций | |
| JP2021510733A5 (https=) | ||
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| RU2008139195A (ru) | Замещенные арилсульфанамиды как противовирусные средства | |
| RU2015117647A (ru) | Новые производные пиразола |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20091001 |